Tools / Drug approvals and letters / Drugs Methotrexate Sodium Treats acute lymphoblastic leukemia. Sold as Methotrexate Sodium, Methotrexate Lpf, Methotrexate Sodium Preservative Free, Methotrexate Preservative Free, Xatmep. Every FDA application for this active ingredient: 3 branded and 58 generic.
As of Nov 15, 2026, FDA lists 61 applications for Methotrexate Sodium (sold as Methotrexate Sodium, Methotrexate Lpf, Methotrexate Sodium Preservative Free and others), first approved Dec 7, 1953, with 4 new uses approved and 0 published complete response letters.
First approved : Dec 7, 1953 Applications : 61 New uses approved : 4 Complete response letters : 0 Medicare spending, 2025 : $57.6M First approved in the EU : Aug 18, 2016 Shortage : Current
Medicare Spending CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name Product Part Spending, 2025 Change Beneficiaries Methotrexate Part D $55.1M -4% 569,550 Trexall Part D $2.4M +3% 1,931 Methotrexate (J9260) Part B $112K +8% 4,602 Methotrexate (J8610) Part B $2K -37% 96
What Pharmacies Pay Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change METHOTREXATE 2.5 MG TABLET: $0.163 per unit Generic · +4% in a year METHOTREXATE 250 MG/10 ML VIAL: $0.702 per ML Generic · -64% in a year METHOTREXATE 50 MG/2 ML VIAL: $1.75 per ML Generic · +5% in a year XATMEP 2.5 MG/ML ORAL SOLUTION: $21.76 per ML Brand · new this year FDA Drug Safety Communications One communication since 2020 that name this drug; see all communications Treatment of non-infectious intermediate, posterior, or pan uveitis or chronic non-infectious anterior uveitis Nordic Group B.V. · designated Oct 4, 2023 Treatment of retinitis pigmentosa Aldeyra Therapeutics, Inc. · designated Jul 21, 2021 Treatment of Primary Vitreoretinal Lymphoma Aldeyra Therapeutics, Inc. · designated Jul 19, 2021 Treatment of ectopic pregnancy Antares Pharma, Inc · designated Mar 25, 2019 Prevention of proliferative vitreoretinopathy (PVR) Aldeyra Therapeutics, Inc. · designated Apr 11, 2018 Treatment of Myasthenia Gravis The Universtiy of Kanasa Medical Center · designated Aug 28, 2014 Treatment of acute lymphoblastic leukemia Orbona Pharma Ltd · designated Aug 20, 2009 Treatment of juvenile rheumatoid arthritis. Wyeth-Ayerst Laboratories · designated Aug 23, 1993 Approvals in the EU (EMA) First approved in the EU 752 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals Metoject, new approval Drugs with a new indication and a new dosage in an additional dosage form for the treatment of rheumatoid arthritis. · nippon medac Co., Ltd. · Sep 26, 2022 Rheumatrex A drug with new additional indications and a new dosage for the treatment of plaque psoriasis in patients who have not responded sufficiently to topical… · Pfizer Japan Inc. · Mar 26, 2019 Rheumatrex Drugs with a revised indication and an expanded dosage for the treatment of rheumatoid arthritis (limitation of patients to be treated was abolished). · Sawai Pharmaceutical Co., Ltd. · Feb 23, 2011 Rheumatrex Drugs with a new indication and a new dosage for the treatment of juvenile idiopathic arthritis accompanied by articular symptoms. · Mitsubishi Tanabe Pharma Corporation · Sep 24, 2008
Shortages FDA's drug shortage list, as of Nov 13, 2026 Clinical Trials 12 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all Study Phase Status Posted Methotrexate Treatment in Hand Osteoarthritis Refractory to Usual Treatments Erosive Hand Osteoarthritis · Centre Hospitalier Universitaire de Nice Phase 2 / Phase 3 Recruiting Mar 30, 2026 Use of Letrozole for Ectopic Pregnancy Ectopic Pregnancy · Hospital de Clinicas de Porto Alegre Phase 4 Recruiting Apr 9, 2024 A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome · Children's Oncology Group Phase 1 Recruiting Feb 8, 2024 A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia · Children's Oncology Group Phase 2 Active, not recruiting Mar 9, 2023 Venetoclax Basket Trial for High Risk Hematologic Malignancies Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary · Andrew E. Place, MD Phase 1 Recruiting Mar 23, 2022 Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia · University of Chicago Phase 2 Recruiting Feb 10, 2021 A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia · National Cancer Institute (NCI) Phase 2 Recruiting Sep 14, 2020 Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · National Cancer Institute (NCI) Phase 3 Active, not recruiting Aug 28, 2020
Applications NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history Approved Application Sponsor Supplements Marketing Dec 7, 1953 Methotrexate Sodium NDA 8085 · New molecular entity Strides Pharma Intl38 Discontinued Aug 10, 1959 Methotrexate Sodium, Methotrexate Lpf NDA 11719 · New active ingredient Hospira73 Marketed Sep 5, 1979 Mexate ANDA 86358 Bristol9 Discontinued Feb 14, 1985 Mexate-Aq ANDA 88760 Bristol Myers5 Discontinued May 9, 1986 Methotrexate Sodium ANDA 88648 Norbrook0 Discontinued Jun 13, 1986 Methotrexate Sodium ANDA 89263 Abraxis Pharm2 Discontinued Jun 13, 1986 Methotrexate Sodium ANDA 89322 Abraxis Pharm2 Discontinued Jun 13, 1986 Methotrexate Sodium ANDA 89323 Abraxis Pharm2 Discontinued Sep 16, 1986 Methotrexate Sodium Preservative Free ANDA 89340 Hikma21 Marketed Sep 16, 1986 Methotrexate Sodium ANDA 89341 Hikma21 Marketed Sep 16, 1986 Methotrexate Sodium ANDA 89342 Hikma20 Marketed Sep 16, 1986 Methotrexate Sodium Preservative Free ANDA 89343 Hikma19 Marketed Jul 8, 1988 Methotrexate Sodium ANDA 89158 Pharmachemie USA3 Discontinued Apr 14, 1989 Mexate-Aq Preserved ANDA 89887 Bristol Myers Squibb1 Discontinued Oct 15, 1990 Methotrexate Sodium ANDA 81099 Barr32 Marketed Aug 23, 1991 Folex Pfs ANDA 81242 Pharmacia And Upjohn0 Discontinued May 15, 1992 Methotrexate Sodium ANDA 81235 Mylan16 Marketed Aug 1, 1994 Methotrexate Sodium ANDA 40054 Hikma9 Marketed Feb 26, 1999 Methotrexate Preservative Free ANDA 40266 Fresenius Kabi USA8 Marketed Feb 26, 1999 Methotrexate Sodium ANDA 40263 Fresenius Kabi USA8 Marketed Feb 26, 1999 Methotrexate Preservative Free ANDA 40265 Fresenius Kabi USA7 Discontinued Jun 17, 1999 Methotrexate Sodium ANDA 40233 Duramed Pharms Barr2 Discontinued Mar 21, 2001 Trexall ANDA 40385 Barr7 Marketed Aug 12, 2005 Methotrexate Sodium Preservative Free ANDA 40632 Hikma4 Marketed Apr 30, 2007 Methotrexate Sodium Preservative Free ANDA 40716 Accord Hlthcare5 Marketed Apr 30, 2007 Methotrexate Sodium Preservative Free ANDA 40767 Accord Hlthcare5 Marketed Apr 30, 2007 Methotrexate Sodium Preservative Free ANDA 40768 Accord Hlthcare5 Marketed Mar 31, 2009 Methotrexate Sodium Preservative Free ANDA 90029 Caplin One Labs5 Discontinued Mar 31, 2009 Methotrexate Sodium Preservative Free ANDA 90039 Caplin One Labs5 Discontinued Jan 8, 2010 Methotrexate Sodium Preservative Free ANDA 40843 Pharmachemie BV6 Marketed Mar 29, 2012 Methotrexate Sodium Preservative Free ANDA 201530 Extrovis3 Discontinued Mar 29, 2012 Methotrexate Sodium Preservative Free ANDA 201529 Eugia Pharma Speclts4 Marketed May 21, 2015 Methotrexate Sodium ANDA 201749 Sun Pharm4 Marketed Jan 13, 2017 Methotrexate Sodium ANDA 207812 Zydus Pharms3 Marketed Apr 25, 2017 Xatmep NDA 208400 · New dosage form Azurity2 Marketed Dec 22, 2017 Methotrexate Sodium ANDA 210040 Amneal Pharms3 Discontinued Aug 9, 2018 Methotrexate Sodium Preservative Free ANDA 203407 Sagent Pharms Inc1 Marketed Jan 24, 2020 Methotrexate Sodium ANDA 213343 Accord Hlthcare2 Marketed Jan 30, 2020 Methotrexate Sodium ANDA 210454 Eugia Pharma3 Marketed Apr 23, 2021 Methotrexate Sodium ANDA 209787 Lotus Pharm Co Ltd0 Discontinued Aug 7, 2023 Methotrexate Sodium ANDA 213362 Daito1 Discontinued May 16, 2024 Methotrexate Sodium ANDA 216453 Elite Labs Inc1 Marketed Jun 3, 2024 Methotrexate Sodium ANDA 217552 Alembic1 Marketed Apr 15, 2026 Methotrexate Sodium ANDA 220225 Alembic0 Marketed Apr 30, 2026 Methotrexate Sodium ANDA 219865 Hetero Labs Ltd Vi0 Marketed — Folex ANDA 87695 Pharmacia And Upjohn0 Discontinued — Methotrexate Sodium ANDA 88935 Abraxis Pharm1 Discontinued — Methotrexate Sodium ANDA 88936 Abraxis Pharm1 Discontinued — Methotrexate Sodium ANDA 88937 Abraxis Pharm1 Discontinued — Folex ANDA 88954 Pharmacia And Upjohn0 Discontinued — Abitrexate ANDA 89161 Abic0 Discontinued — Folex Pfs ANDA 89180 Pharmacia And Upjohn0 Discontinued — Methotrexate Sodium ANDA 89293 Quad Pharms0 Discontinued — Methotrexate Sodium ANDA 89294 Quad Pharms0 Discontinued — Methotrexate Sodium ANDA 89295 Quad Pharms0 Discontinued — Methotrexate Sodium ANDA 89296 Quad Pharms0 Discontinued — Methotrexate Sodium ANDA 89308 Quad Pharms0 Discontinued — Methotrexate Sodium ANDA 89309 Quad Pharms0 Discontinued — Abitrexate ANDA 89354 Abic0 Discontinued — Abitrexate ANDA 89355 Abic0 Discontinued — Abitrexate ANDA 89356 Abic0 Discontinued
Show all 61Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA